Daré Bioscience Inc. has released its financial results for the first quarter of 2025. The company reported a cash position of approximately $10.3 million as of March 31, 2025, with a working capital deficit of approximately $9.4 million. General and administrative expenses decreased to $2.3 million in Q1 2025 from $2.7 million in the same quarter of the previous year. This decrease was primarily due to reductions in stock-based compensation expense, professional services expense, and personnel costs. Research and development expenses also saw a significant decrease, amounting to $2.3 million in Q1 2025 compared to $3.4 million in Q1 2024. The 31% decrease was mainly due to reduced manufacturing costs related to Ovaprene, as well as decreased costs for development activities of Sildenafil Cream and preclinical stage programs. In addition to these financial results, Daré Bioscience is taking steps to commercialize multiple solutions by 2025 and 2026, including two vaginal probiotics and a proprietary monthly hormone therapy. The company anticipates capitalizing on a commercial opportunity in the estimated up to $4.5 billion compounded hormone therapy market. Daré expects to begin recording revenue in the fourth quarter of this year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.